Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs.All members of the Ras protein family are involved in signal transmission within cells and are members of the small GTPase protein class. Ras is the representative member of the Ras superfamily, a group of proteins that all share a common 3D structure and control a variety of cell behaviors. Incoming signals that activate Ras then activate other proteins, which in turn activate genes necessary for cell growth, differentiation, and survival. Ras proteins that are permanently activated can therefore be produced as a result of ras gene mutations.Even in the absence of incoming signals, this may result in unintended and excessive signaling within the cell. Overactive Ras signaling can ultimately result in cancer because these signals cause cell growth and division. The most prevalent oncogenes in human cancer are the 3 Ras genes (HRAS, KRAS, and NRAS), and Ras inhibitors are being researched as a potential treatment for cancer and other conditions characterized by Ras overexpression.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V51444 | PROTAC KRAS G12C degrader-2 | 2378257-72-6 | PROTAC KRAS G12C degrader-2 is a K-Ras protein hydrolysis modulator. | |
V51460 | PROTAC SOS1 degrader-1 | 2913185-35-8 | PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 degrader with an DC50 of 98.4 nM. | |
V51478 | PROTAC SOS1 degrader-3 | PROTAC SOS1 degrader-3 is a potent degrader of PROTAC SOS1. | ||
V76568 | Rac1 Inhibitor W56 TFA | Rac1 Inhibitor W56 TFA is residues 45-60 in Rac1. | ||
V13613 | Ras-IN-3144 | 1835283-94-7 | Ras-IN-3144 is a novel and potent pan-RAS inhibitor which disrupts the interaction of Ras proteins and their effectors, also inhibits RAS signaling pathways in cancer cells and prevents the growth of RAS mutant mouse cancer xenografts. | |
V50932 | RM-018 | 2641993-55-5 | RM-018 is a novel tricomplex KRASG12C active-state inhibitor that has different functional properties. | |
V50901 | RMC-0331 | 2488788-52-7 | RMC-0331 is a novel and orally active inhibitor of SOS1. | |
V51194 | RMC-6236 | 2765081-21-6 | RAS-IN-2 (Compound A122) is a potent RAS(ON)MULTI inhibitor that may be utilized in cancer-related research. | |
V51060 | RMC-6291 | RMC-6291 is a covalent and oral inhibitor of KRASG12C(ON). | ||
V51471 | RMC-6291 | 2641998-63-0 | RMC-6291 is a covalent and oral inhibitor of KRASG12C(ON). | |
V51455 | SAH-SOS1A | 1652561-87-9 | SAH-SOS1A is an inhibitor of the SOS1/KRAS protein interaction based on peptides. | |
V51437 | Setidegrasib | 2821793-99-9 | KRAS G12D inhibitor 17 is a quinazoline-linked (4R)-4-hydroxy-L-prolinamide compound that causes the KRAS protein with the G12D mutation to degrade. | |
V51459 | SOS1-IN-14 | 2793405-20-4 | SOS1-IN-14 is a novel, selective, and orally active inhibitor of SOS1 with an IC50 value of 3.9 nM. | |
V51468 | SOS1-IN-15 | 2793404-47-2 | SOS1-IN-15 is a novel, potent and orally bioactive SOS1 inhibitor with an IC50 of 5 nM. | |
V51470 | SOS1-IN-4 | 2738392-83-9 | SOS1-IN-4 is a potent SOS1 inhibitor (antagonist) with IC50 of 56 nM for the KRAS-C12C/SOS1 interaction (WO2021228028 A1, example 65). | |
V51453 | SOS1-IN-5 | 2716956-47-5 | SOS1-IN-5 is a novel SOS1 inhibitor. | |
V51445 | SOS1/KRAS-IN-1 | 2836330-34-6 | SOS1/KRAS-IN-1 is a selective and novel SOS1/KRAS inhibitor that can be applied to the study of illnesses that are mediated by SOS1/KRAS. | |
V4841 | Sotorasib (AMG-510) racemate | 2252403-56-6 | Sotorasib racemate (AMG-510; AMG510), the racemic mixture of AMG-510, is a novel, potent and covalent inhibitor of KRAS G12C. | |
V78326 | Sotorasib-d7 (Sotorasib-d7; AMG-510-d7) | Sotorasib-d7 (AMG-510-d7) is a deuterium-labeled version of Sotorasib. | ||
V51456 | Spiclomazine (Clospirazine) | 24527-27-3 | Spiclomazine (Clospirazine) is a novel, selective mutant KRAS(G12C) inhibitor that inhibits pancreatic cancer caused by mutant KRAS in a selective manner. |